ArthroCare Corp.
What medtech companies is BlackRock buying into?
ArthroCare reserves $15M for employees amid Smith & Nephew buyout
ArthroCare’s Q4 misses analysts’ expectations
Smith & Nephew may face rivals in $1.7B bid for ArthroCare
Smith & Nephew expands sports medicine footprint with $1.7B ArthroCare buy
ArthroCare settles $400M fraud scheme with $30M fine
ArthroCare (NSDQ:ARTC) and the U.S. Justice Dept. yesterday agreed to settle the $400 million fraud case against the medical device company with a $30 million fine and a 2-year deferred prosecution deal.
ArthroCare misses the mark with Q3 earnings
ArthroCare (NSDQ:ARTC) missed Wall Street’s forecast for its 3rd-quarter earnings, sending share prices down nearly 3% this week.
Ex-ArthroCare exec changes plea to guilty in stock fraud scheme
Former ArthroCare (NSDQ:ARTC) executive John Raffle changed his plea to guilty last month, admitting to charges that he took part in a scheme to artificially inflate ARTC stock prices by misleading investors.
MassDevice.com +3 | The top 3 med-tech stories for July 18, 2013
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Feds indict ex-ArthroCare CEO, CFO in $400M fraud scheme
Federal prosecutors in Texas indicted the former CEO and CFO of ArthroCare (NSDQ:ARTC) on 17 counts of conspiracy to commit fraud for their alleged roles in running a $400 million scheme designed to defraud investors.